Singapore markets closed
Straits Times Index
3,269.27 -32.69 (-0.99%) Nikkei
28,546.98 +727.65 (+2.62%) Hang Seng
20,175.62 +93.19 (+0.46%) FTSE 100
7,511.31 +45.40 (+0.61%) BTC-USD
23,966.77 -495.68 (-2.03%) CMC Crypto 200
569.62 -5.12 (-0.89%)
Cyclerion Therapeutics, Inc. (CYCN)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
| Previous close | 0.9600 |
| Open | 0.9600 |
| Bid | 0.0000 x 1400 |
| Ask | 0.0000 x 1200 |
| Day's range | 0.9300 - 1.0300 |
| 52-week range | 0.4610 - 3.6230 |
| Volume | |
| Avg. volume | 277,816 |
| Market cap | 42.61M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2350 |
| Earnings date | 24 Feb 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Cyclerion Therapeutics, Inc. (CYCN) Reports Q2 Loss, Misses Revenue Estimates
Cyclerion Therapeutics, Inc. (CYCN) delivered earnings and revenue surprises of 8.82% and 56.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Down 38.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Cyclerion Therapeutics, Inc. (CYCN)
The heavy selling pressure might have exhausted for Cyclerion Therapeutics, Inc. (CYCN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
© 2022 Yahoo. All rights reserved.
